iBio, Inc. (IBIO) Earnings History

iBio, Inc. - Q2 FY2026 Earnings

Filed at: Feb 10, 2026, 4:06 PM EST|Read from source

EXECUTIVE SUMMARY

iBio reported its Q2 FY2026 results, characterized by significant increases in operating expenses and a net loss, driven by R&D and G&A spending. The company secured substantial PIPE financing to extend its cash runway and advance preclinical programs, while also presenting positive preclinical data.

POSITIVE HIGHLIGHTS

  • •

    Closed a $26 million private placement financing led by Frazier Life Sciences, extending cash runway into Q3 FY2028.

    positive
  • •

    Presented new non-human primate (NHP) data on IBIO-610 showing a predicted human half-life of up to 100 days, supporting potential infrequent dosing.

    positive
  • •

    IBIO-600 is completing toxicology studies and on track for Phase 1a clinical trials in H1 CY2026.

    positive
  • •

    IBIO-610 NHP, CMC, and toxicology studies are ongoing and on track for first human clinical trials in early CY2027.

    positive

CONCERNS & RISKS

  • •

    Revenue was $0 for the three months ending December 31, 2025, compared to $0.2 million in the prior year period.

    negative
  • •

    Research and Development expenses increased by $2.4 million to $4.3 million for the quarter, primarily due to increased spending on consultants, outside services, and personnel costs.

    attention
  • •

    General and Administrative expenses increased by $2.5 million to $5.2 million for the quarter, primarily attributable to the impairment of the Company’s indefinite lived intangible asset IBIO-101.

    attention
  • •

    Net loss for the quarter was $9.0 million, a significant increase from $4.4 million in the prior year period.

    negative
  • •

    Loss per common share was $(0.09) for the quarter, compared to $(0.48) in the prior year period, reflecting increased operating expenses.

    negative

FINANCIAL METRICS

Revenue
Quarterly
$0.00
-100.0%
Prior year: $200.00K
Annual (YTD)
$100.00K
N/A
Prior year: $200.00K
Net Income
Quarterly
$-8.99M
-106.1%
Prior year: $-4.36M
Annual (YTD)
$-14.71M
N/A
Prior year: $-8.35M
EPS (Diluted)
Quarterly
$-0.09
+81.3%
Prior year: $-0.48
Operating Income
Quarterly
$-9.45M
-113.7%
Prior year: $-4.42M
Annual (YTD)
$-15.40M
N/A
Prior year: $-8.53M
EPS (Basic)
Quarterly
$-0.09
+81.3%
Prior year: $-0.48

MARGIN ANALYSIS

Margin metrics will be available once backend extracts data from insights_json

SPECIAL ITEMS & ADJUSTMENTS

Q2 FY2026
Impairment of indefinite lived intangible asset IBIO-101
Contributed to increase in G&A expenses.

Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.

MANAGEMENT COMMENTARY

Significantly advanced preclinical pipeline programs (IBIO-610, IBIO-600) towards human clinical trials by initiating CMC development and toxicology studies.

— iBio, Inc., Q2 FY2026 2026 Earnings Call

Completed a $26 million private placement financing, strengthening resources and extending cash runway into Q3 FY2028.

— iBio, Inc., Q2 FY2026 2026 Earnings Call

Presented new NHP data on IBIO-610 showing a predicted human half-life of up to 100 days, supporting potential infrequent dosing.

— iBio, Inc., Q2 FY2026 2026 Earnings Call

Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.

OPERATIONAL METRICS

Cash runway extension
into Q3 FY2028
quarters
IBIO-610 dosing frequency
twice per year
doses/year
IBIO-610 predicted human half-life
up to 100 days

Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.